PCSK9 inhibitors

PCSK9 inhibitors are cholesterol-lowering drugs. They work via the LDL receptors in the liver. These are a kind of "safety net" that removes LDL from your blood.

Normally, the protein PCSK9 causes some of these safety nets to be broken down. PCSK9 inhibitors block this process. As a result, more LDL receptors remain active in the liver. This allows your liver to remove more LDL from your blood, lowering your LDL cholesterol.

According to the American Heart Association, PCSK9 inhibitors (such as evolocumab and alirocumab) can often reduce LDL cholesterol by 50% or more. They are usually administered via injection once every 2 to 4 weeks and are expensive. You are usually only eligible for them if other cholesterol-lowering drugs are not effective enough and you are at high risk of cardiovascular disease.

Interested in the scientific history of PCSK9? In December 2025, a review article was published summarizing the most important steps and insights.